hVIVO PLC (AIM:HVO) chief executive Yamin (Mo) Khan speaks with Proactive's Stephen Gunnion about the company's achievements in the first half of 2024, including a 31% increase in revenue, reaching £35.6 million. Khan highlighted the company's record EBITDA of £8.7 million, reflecting a 68% year-on-year growth. He attributed these successes to the opening of the world’s largest human challenge trial facility in Canary Wharf, which includes 50 beds for CL3 level pathogen trials.
Khan also spoke about hVIVO’s strategic expansion of service offerings beyond human challenge trials, including laboratory services and patient recruitment via its FluCamp platform. He emphasised the company’s strong order book, valued at £71 million, and its sales pipeline, which includes £40 million worth of opportunities.
As hVIVO looks ahead, Khan reiterated the company’s guidance for 2024 revenue of £62 million and an EBITDA margin at the upper end of market expectations. With an optimistic outlook for future growth, hVIVO remains on track to achieve its 2028 target of £100 million.